Brokerages Expect Myomo, Inc. (NASDAQ:MYO) to Post -$0.17 EPS

Wall Street brokerages forecast that Myomo, Inc. (NASDAQ:MYO) will report ($0.17) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Myomo’s earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.15). Myomo reported earnings of ($0.21) per share in the same quarter last year, which indicates a positive year over year growth rate of 19%. The firm is expected to report its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Myomo will report full-year earnings of ($0.64) per share for the current fiscal year, with EPS estimates ranging from ($0.69) to ($0.58). For the next financial year, analysts expect that the company will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.59) to ($0.35). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Myomo.

Myomo (NASDAQ:MYO) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.03. The company had revenue of $0.83 million during the quarter, compared to analyst estimates of $0.86 million.

Shares of NASDAQ MYO traded down $0.06 during mid-day trading on Wednesday, reaching $0.76. The company had a trading volume of 56,300 shares, compared to its average volume of 89,752. Myomo has a twelve month low of $0.74 and a twelve month high of $3.09. The stock has a 50 day simple moving average of $0.92.

Myomo Company Profile

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Read More: Why are percentage decliners important?

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.